Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Section
Access a regularly updated listing of late-stage clinical trials of high relevance to clinicians who provide care to patients who have or are at risk for osteoporosis. Featured in the most recent update are studies on postmenopausal osteoporosis, secondary osteoporosis, osteoporosis in men, hip and vertebral fracture prevention, and therapeutic agents such as bisphosphonates, calcitonin, denosumab, estrogen, odanacatib, parathyroid hormone analogs, estrogen receptor agonists/antagonists, and other drugs in development.
Estrogen Receptor Agonists/Antagonists
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Conditions: Endometrial Hyperplasia; Osteoporosis
Interventions: Drug: Bazedoxifene/Conjugate Estrogens (CE); Drug: Raloxifene; Drug: Placebo
Sponsor: Wyeth
Completed - verified May 2008
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: Raloxifene HCL; Drug: Raloxifene HCL; Drug: Placebo
Sponsor: Eli Lilly and Company
Completed - verified April 2008
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
Condition: Osteoporosis
Intervention: Drug: Bazedoxifene Acetate (TSE-424)
Sponsor: Wyeth
Completed - verified August 2009
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, /Duration of Treatment : 12 Months; Drug: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
Sponsor: Merck
Completed - verified September 2008
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: Arzoxifene; Drug: Raloxifene
Sponsor: Eli Lilly and Company
Completed - verified January 2010
3-Year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-Menopausal Women
Condition: Osteopenia
Interventions: Drug: Menostar (Estradiol, BAY86-5435); Drug: Raloxifene
Sponsor: Bayer
Completed - verified July 2009
Study Evaluating Bazedoxifene Acetate in Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Bazedoxifene Acetate; Drug: Raloxifene; Other: Placebo
Sponsor: Wyeth
Active, not recruiting - verified May 2010
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
Condition: Osteoporosis
Interventions: Drug: lasofoxifene; Drug: raloxifene; Drug: placebo
Sponsor: Pfizer
Completed - verified March 2006
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: Raloxifene
Sponsor: University of Wisconsin, Madison
Completed - verified March 2006
Vitamin K and Bone Turnover in Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: phylloquinone (K1); Drug: menatetranone (MK4)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eisai Limited
Completed - verified March 2010
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: teriparatide; Drug: raloxifene; Drug: placebo
Sponsor: Eli Lilly and Company
Completed - verified July 2006
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
Conditions: Menopause; Osteoporosis
Interventions: Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; Drug: bazedoxifene 20 mg; Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Drug: Placebo
Sponsor: Wyeth
Active, not recruiting - verified September 2010
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Conditions: Endometrial Hyperplasia; Osteoporosis
Interventions: Drug: Bazedoxifene/Conjugate Estrogens (CE); Drug: Raloxifene; Drug: Placebo
Sponsor: Wyeth
Completed - verified May 2008
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
Condition: Osteoporosis
Intervention: Drug: Bazedoxifene Acetate (TSE-424)
Sponsor: Wyeth
Completed - verified August 2009
Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
Conditions: Postmenopause; Osteoporosis
Intervention: Drug: bazedoxifene BZA-20
Sponsor: Wyeth
Completed - verified May 2007
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Conditions: Endometrial Hyperplasia; Osteoporosis
Interventions: Drug: Bazedoxifene/Conjugated Estrogen; Other: Placebo
Sponsor: Wyeth
Completed - verified June 2010
Study Evaluating Bazedoxifene Acetate in Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Bazedoxifene Acetate; Drug: Raloxifene; Other: Placebo
Sponsor: Wyeth
Active, not recruiting - verified May 2010
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
Condition: Osteoporosis
Interventions: Drug: lasofoxifene; Drug: raloxifene; Drug: placebo
Sponsor: Pfizer
Completed - verified March 2006
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
Condition: Osteoporosis
Interventions: Drug: lasofoxifene; Other: placebo; Drug: lasofoxifene
Sponsor: Pfizer
Completed - verified May 2008
